Drug intelligence / Profile preview

F#13418-158 Eye Drops

Development stage: Unknown
Lead developer: Johnson & Johnson
Administration: Ophthalmic

Overview

F#13418-158 Eye Drops is an investigational drug candidate developed by Johnson & Johnson, currently in Phase 3 clinical trials. It is being evaluated for its efficacy as an over-the-counter (OTC) eye drop, specifically in healthy adults with red eyes. The drug is administered ophthalmically. Details regarding its specific mechanism of action and active pharmaceutical ingredient have not been publicly disclosed. The clinical trial NCT03198000, a double-blinded study, aimed to demonstrate the therapeutic equivalence of this investigational product.

Beyond the preview

Go deeper on F#13418-158 Eye Drops.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on F#13418-158 Eye Drops.

Explore the full profile